 |
|
|
| |
Identification and Management of Drug-Drug Interactions (DDIs)
by a Clinical Pharmacist in Patients Prescribed Hepatitis C Virus (HCV) Treatment
|
| |
| |
Reported by Jules Levin
PK-Wk: High risk on drug-drug interactions during hepatitis C treatment: a nationwide cohort - (06/13/15)
17th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy June 8-10, 2016, Washington DC
17th International Workshop on
Clinical Pharmacology of HIV and Hepatitis Therapy
8 - 10 June 2016, Washington DC, USA
Jacob A. Langness1,2, Matthew Q. Nguyen2, Amanda Wieland3, Gregory T. Everson3, and Jennifer J. Kiser2
1.University of Colorado Health, Aurora, CO 2.University of Colorado Skaggs School of Pharmacy, Aurora, CO 3.University of Colorado School of Medicine, Aurora, CO
|
| |
|
|
|
|
|
